Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This study investigated the pharmacokinetics (how a drug is taken up and excreted from the
body), safety, and tolerability of 2 new tapentadol (CG5503) tablet formulations compared to
a previously characterized tapentadol prolonged-release (PR) tablet formulation.